A B S T R A C T We have previously shown that the erythroagglutinating phytohemagglutinin (E-PHA) from Phaseolus vulgaris binds to the surface of intact human platelets and that adenylate cyclase activity in the particulate fraction of E-PHA-treated platelets is lower than in comparable controls. We now find that E-PHA induces release of ["C]serotonin from platelets. Release follows binding of E-PHA, and a haptenic inhibitor of E-PHA binding prevents induction of release. E-PHA does not produce platelet lysis and has little effect on ["C]serotonin uptake. Platelets possess approximately 300,000 receptor sites for E-PHA per cell, and we estimate that about 15% of these sites must be occupied by E-PHA to initiate the release reaction. Prior incubation of platelets with prostaglandin E2, theophylline, or dibutyryl cyclic AMP prevents E-PHA-induced release, although these agents have little effect on E-PHA binding to platelets. Thrombin and E-PHA produce different rates and extents of serotonin release. Thrombin (1 U/ml) causes release of 75-85% of platelet ["C]-serotonin, with half-maximal release occurring less than 0.5 min after thrombin addition. E-PHA, however, induces release of only 30-60% of platelet serotonin at a 10-fold slower rate. In addition, utilizing electron microscopy, we have observed striking differences in* the morphological changes that occur in platelets exposed to E-PHA as compared with thrombin. Thus, the platelet release reaction may be triggered in part by binding of E-PHA to the cell surface, but this reaction only partially resembles that produced by thrombin.
INTRODUCTION
Platelet function during hemostasis is characterized by two interrelated processes: (a) aggregation and (b) the "release reaction," in which adenine nucleotides, serotonin, certain proteins, and other compounds are released from the cells (1) . Thrombin induces both platelet aggregation and release in suspensions of washed human platelets. The mechanism by which thrombin produces these effects remains unknown, although we have postulated that thrombin acts at the platelet surface to initiate these reactions (2) . Previous experiments demonstrated that thrombin inactivates membrane-bound adenylate cyclase when added to intact platelets and that this inactivation is inhibited by preincubation of the cells with agents which elevate cAMP' levels (3). We previously suggested that the substrate for thrombin in the platelet membrane might be the 190,000 dalton glycoprotein designated thrombin-sensitive protein (2) . More recent experiments indicate that this protein is released intact from the membrane fraction of the cell after thrombin treatment (4) , and, therefore, it is probably not the thrombin substrate. Thus, the mechanism of the thrombin reaction remains obscure.
A variety of other agents, including collagen, ADP, antigen-antibody complexes, venoms, and other proteases produce platelet aggregation and/or the release reaction (1) . We have recently reported the binding of several phytohemagglutinins to the platelet plasma membrane and have reported that two of these compounds from Phaseolus vulgaris designated erythroagglutinating phytohenmagglutinin (E-PHA) and leukoagglutinating 1 Abbreviations used in this paper: cAMP, cyclic adenosine 3',5'-monophosphate; dibutyryl cAMP (DB-cAMP), N"-2'-0-dibutyryll cyclic adenosine 3',5'-monophosphate; PGE1, prostaglandin E,; E-PHA, erythroagglutinating phytohemagglutinin of Pliaseolus vulgaris; lentil-PHA, lentil phytohemagglutinin.
The Journal of Clinical Investigation Volume 53 January 1974.211-218 phytohemagglutinin (L-PHA) inhibit adenylate cyclase and induce release of thrombin-sensitive protein after binding to human platelets (5) . Since, in contrast to thrombin these phytohemagglutinins presumably have no proteolytic activity, we have attempted to delineate the mechanism and extent of the effects these compounds produce when added to platelets to elucidate further the mechanism of the platelet release reaction. Herein we report experiments that examine the E-PHA-induced release reaction in human platelets.
METHODS
Materials. E-PHA was purified from Bacto phytohemagglutinin-P (Difco Laboratories, Detroit, Mich.) and labeled with "2I as previously reported (5). Protein concentration was estimated by measuring absorbance at 280 nm, assuming 1.0 absorbance unit = 1 mg/ml of protein.
The molecular weight of E-PHA was assumed to be 128,000 (6) . Bovine thrombin was purified from topical thrombin (Parke, Davis & Company, Detroit, Mich.) by the method of Glover and Shaw (7), which yielded a fibrinogen-clotting activity of 2,000-2,500 NIH U/mg of protein.
[ were purchased from Millipore Corp., Bedford, Mass.
Isolation of platelets. Platelets were isolated from 60-70 ml of human blood as follows: Whole blood was placed in 50-ml plastic centrifuge tubes containing Na2EDTA (5 mM final concentration) and centrifuged for 3 min at 1,400 g. The supernatant platelet-rich plasma was centrifuged at 2,250 g for 15 min and the resulting pellet was resuspended in 40 ml of isotonic phosphate-buffered saline (pH 6.5) containing 0.113 M NaCl, 0.0043 M K .HPO4, 0.0043 M Na2HPO4, 0.0244 M NaH2PO4, and 0.0055 M glucose. The platelet suspension was then centrifuged at 120 g for 10 min to remove contaminating leukocytes and erythrocytes. The pellet of erythrocytes and leukocytes was resuspended in phosphate-buffered saline (pH 6.5) and centrifuged at 120 g for 10 min to recover platelets that sedimented in the first 120 g spin. The platelets were then washed twice in phosphate-buffered saline by centrifugation at 2,250 g for 15 min and finally resuspended in isotonic Tris-buffered saline (pH 7.5) containing 0.14 M NaCl, 0.015 M Tris-HCl, and 0.0055 M glucose at 3-6 X 109 platelets/ml. The platelet concentration was estimated by spinning an aliquot of the final 'suspension in a microhematocrit centrifuge, assuming that a 1% packed cell volume equals 109 cells/ml. The entire isolation procedure was performed at room temperature, plastic centrifuge tubes and pipettes were used throughout, and subsequent experiments were completed within 8 h of the time the blood was drawn.
Platelets for electron microscopy were suspended in isotonic cacodylate-buffered saline (pH 6.8) containing 0.14 M NaCl, 0.015 M sodium cacodylate-HCl, 0.0055 M glucose, and 5 mg/ml bovine serum albumin. Albumin (5 mg/ ml) was also present in the phosphate-buffered saline used to wash these platelets. These modifications had little effect on platelet aggregation or release of serotonin induced by E-PHA or by thrombin. Binding of E-PHA to platelets. Reaction mixtures containing 0.5 x 108 platelets in 0.5 ml of Tris-buffered saline (pH 7.5) were incubated at room temperature with "Ilabeled E-PHA. Additional substances were also present in some cases as indicated below. After a given length of time the incubation was terminated by the addition of 5 ml of ice-cold buffer, and the platelets were collected immediately by filtration through a Millipore filter under reduced pressure. The filter was Washed once with 5 ml of cold buffer and counted in a Packard autogamma counter, Packard Instrument Co., Inc., Downers Grove, Ill.
Plastic tubes (12 X 75 mm) and Millipore filters used in these experiments were soaked in 0.5% bovine serum albumin for at least 2 h before use to reduce adsorption of iodinated phytohemagglutinin (5 Platelets possess approximately 300,000 E-PHA receptor sites per cell as determined in this paper' by the method of Steck and Wallach (11), and we estimate that at the concentration of E-PHA used in the experiment in Fig. 1 (156 nM total) about 90% of these receptors are occupied at equilibrium.
Higher concentrations of E-PHA produce no further serotonin release as indicated in Fig. 2 . However, at E-PHA concentrations below about 40 nM, the amount of serotonin released in 60 min is decreased. Below about 5 nM E-PHA little if any serotonin is released from platelets in a 60 min incubation.
We have correlated serotonin release with the percentage of total E-PHA receptor sites that have E-PHA bound to them (Fig. 2) . Equilibrium of binding was attained within 20 min at each level of E-PHA tested. Maximal serotonin release is observed when 50% of E-PHA receptors are occupied by E-PHA. On the other hand, about 5-15% of the receptors must bind E-PHA in order for any measurable release to occur within a 60 min incubation period. Half maximal release occurs when approximately 25% of the E-PHA receptors are occupied. Time course experiments at low concentrations of E-PHA (< 40 nM) indicate that the release of serotonin continues beyond 60 min at a very low rate. It is therefore impossible to conclude from these data whether the degree of E-PHA binding affects both the rate and the maximum extent of release or the rate of release only.
The glycoprotein fetuin is a haptenic inhibitor of E-PHA binding to platelets (5) . Fetuin should therefore prevent E-PHA induction of serotonin release if this process depends upon E-PHA binding to platelets. Addition of fetuin at a final concentration of 0.22 mM (10 mg/ml) reduced the binding of E-PHA by 91% and 2 The number of E-PHA receptor sites per platelet differs slightly from that previously reported (500,000-600,000 [5] ). This difference is probably due to a variety of factors including the method of counting the platelets. In this work we estimated platelet concentration by the microhematocrit method, whereas before platelets were counted directly. Furthermore, the E-PHA used in these experiments was purified from a different lot of Difco phytohemagglutinin-P. Differences of 10-30%o are seen using different platelet preparations although results obtained using a single preparation are highly reproducible (±+5-10%). prevented the release of serotonin (Table I) . To exclude the possible presence in the E-PHA preparation of a contaminating proteolytic enzyme, which could itself induce the release of serotonin and which might be competitively inhibited by such a high concentration of protein (10 mg/ml), the experiment was repeated with the addition of albumin (10 mg/ml) in place of fetuin. As shown in Table I , albumin inhibited neither [E-PHA total] (nM) FIGURE 2 Degree of E-PHA binding to platelet receptors and the release of ["C] serotonin. Incubations were conducted as in Fig. 1 16 nmnol NAD+ formed/min/ml after a 2 h incubation of platelets (10' cells/ml) with E-PHA (50 nM), compared with 14 nmol/min/ml in control suspensions (no E-PHA) and 125 nmol/min/ml after lysis of the cells by sonication. Glucose-6-phosphate dehydrogenase activity was not detectable in the supernate after a 1 h incu- Platelets were incubated for 30 min after the addition of E-PHA as in Table I . Other compounds were added 3 or 30 min before E-PHA as indicated.
bation with E-PHA or in control supernates, while an activity of 13 nmol NADPH formed/min/ml was present after sonication. These results indicate that E-PHAinduced serotonin release is not a consequence of cell lysis. It might also be possible for E-PHA to cause net loss of serotonin from platelets by inhibiting the reuptake of serotonin lost from the cells by passive leakage (12) . We find that the rate of [14C]serotonin uptake is about 25-fold lower under conditions used to study release (see Methods) than under conditions employed in labeling the cells initially, which may be due in part to the lower temperature at which release experiments are performed. We also find that E-PHA has no effect on serotonin uptake under the former conditions. Thus, inhibition of serotonin uptake is not a factor in the observed net loss of serotonin from platelets after E-PHA treatment.
Effects of PGE,, theophylline, and DB-cAMP. Since we have shown that E-PHA decreases adenylate cyclase activity in platelets (3), we were interested in determining whether agents that raise intracellular cAMP levels would inhibit E-PHA-induced release of serotonin. The data in Table II The effect of these agents on the binding of E-PHA to platelets is shown in Fig. 3 . The data indicate that in the absence of these agents platelets possess about 300,000 receptor sites per cell for E-PHA which binds with an apparent dissociation constant of 13 nM. Preincubation of platelets with DB-cAMP, PGE1 or theophylline apparently decreases the number of E-PHA receptor sites to about 240,000 per platelet without affecting the time course or the affinity of binding. Thus, while these compounds inhibit serotonin release, they do not prevent E-PHA binding.
Kinetics of ["C]serotonin release induced by E-PHA and by thrombin. The maximum extent of serotonin release induced by E-PHA varies between 30 and 60% with different platelet preparations (see Figs. 1, 2, and 4). In contrast, thrombin consistently induces the release of 75-85% of platelet serotonin. We present a comparison of the kinetics of serotonin release induced by E-PHA and by thrombin using a single platelet preparation in Fig. 4 . The concentrations of both E-PHA (256 nM) and thrombin (1 U/ml) were sufficient to produce the maximum obtainable response in this platelet preparation. E-PHA differs from thrombin both in the extent and in the rate of serotonin release. In this experiment the extent of release is 56% for E-PHA and 81% for thrombin. The half time of thrombininduced release is less than 0.5 min, while for E-PHA it is about 7.5 min. In addition, Fig. 4 shows the effect of thrombin on platelets which are nearly saturated with E-PHA molecules and which have undergone E-PHAinduced release of serotonin. Thrombin is capable of releasing additional serotonin, although the rate of release is somewhat less than that observed with thrombin alone. The total amount of serotonin released by E-PHA followed by thrombin is equal to the amount released by thrombin alone.
Morphological changes in platelets incubated with E-PHA and with thrombin. Although E-PHA and thrombin can each initiate the platelet release reaction, the experiments described above indicate that the effects of these two compounds differ with respect to the maximum extent of release and the rate of release of serotonin. To investigate further the effects produced by E-PHA and thrombin, we have utilized the technique of electron microscopy.
Control platelets (Figs. 5a and 5b ) isolated by our techniques are similar in shape and ultrastructural detail to those described by others (13) . Such canalicular system is prominent, with channels extending throughout the platelet. Granules are readily identified and microtubules are frequently seen (in cross section or sectioned longitudinally) in a circumferential band near the cytoplasmic membrane. Platelets treated with thrombin (2 U/ml, 2 min before fixation) become spherical with central movement of the peripheral microtubular system and develop many elongated pseudopods (Fig. 5c) . Degranulation occurs uniformly and is nearly complete in all platelets. Reorganization of the canalicular system occurs with the formation of a dense conglomerate of amorphous material at the center of the platelet. Microtubules and microfilaments are frequently associated with this material.
E-PHA-treated platelets (413 nM, 30 min before fixation) also become spherical with loss of peripheral microtubules, but in contrast with thrombin-treated platelets, they form few elongated pseudopods (Fig. Sd) .
Degranulation occurs less uniformly than in thrombintreated platelets, although nearly all of the platelets become degranulated to some extent. The canalicular system reorganizes, forming a system of thin, coiled channels, but it does not become densely packed at the center of the cell as in thrombin-treated platelets. Very few microtubules are seen in the cytoplasm of E-PHAtreated platelets. In other experiments we have observed that E-PHA reverses pseudopod formation in thrombintreated platelets. Thirdly, kinetic experiments indicate that release of serotonin from platelets is subsequent to the binding of E-PHA (Fig. 1) . Moreover, fetuin, a glycoprotein that inhibits E-PHA binding to platelets, prevents the induction by E-PHA of serotonin release (Table I) (15) , adenine nucleotides (15) , and thrombin-sensitive protein (3). We previously demonstrated that adenylate cyclase activity in the particulate fraction of E-PHA-treated platelets is lower than in untreated controls (5) , and our present results indicate that preincubation of platelets with PGEi, DB-cAMP, or theophylline inhibits the release of serotonin induced by E-PHA (Table II) (16) .
Previous studies have suggested that the release reaction is accompanied by conformational changes in the platelet plasma membrane. We have found that thrombin produces an apparent twofold increase in the number of receptor sites available for lentil-PHA binding on the platelet surface (5). In addition, thrombin causes the release from platelet membranes of a 190,000 dalton glycoprotein designated thrombin-sensitive protein (2, 4) . We do not know whether these changes occur as an immediate result of the action of thrombin or at some later stage in the release process. In the present work we have obtained indirect evidence suggesting that the release reaction is also accompanied by changes in the number of E-PHA receptor sites available for binding. When we performed studies to determine the effect of inhibitors of the release reaction on E-PHA binding (Fig. 3) , the number of E-PHA receptor sites appeared to be about 25% greater in the absence than in the presence of these inhibitors.' The concentrations (23-154 nM) of E-PHA used in these binding studies were sufficient to produce maximal release of serotonin in the absence of inhibitors (see Fig. 2 ). Thus, it appears that the number of E-PHA receptor sites increases during the release reaction.
We have observed several differences in the effects of E-PHA and thrombin on platelets. Both the rate and the extent of release produced by E-PHA are less than those produced by thrombin (Fig. 4) . In addition, E-PHA does not cause platelet pseudopod formation, nor does it cause central movement of the canalicular system and other organelles (Fig. 5) . These morphological changes are seen in platelets treated with thrombin (Fig. 5) , and the rearrangement of the protein subunits of microtubules or microfilaments is thought to be associated with these processes (13) . These differences might be related to the fact that thrombin is a proteolytic enzyme, whereas E-PHA has no known proteolytic activity. Thus, it appears that E-PHA is capable of activating only a portion of the release reaction (i.e., that which is mediated by cAMP). E-PHA might therefore be a useful tool in further studies designed to elucidate the platelet release reaction.
'Tollefsen, D. M., and P. W. Majerus. Unpublished observations.
It is highly unlikely that the three inhibitors tested, which are structurally unrelated, could each directly interfere with E-PHA binding.
